Omirex

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Omirex

Understanding Omirex

Omirex is a pharmacological agent belonging to the class of medications known as proton pump inhibitors (PPIs). It is primarily utilized to manage conditions associated with excessive gastric acid production. By targeting the acid-producing mechanisms within the stomach lining, it helps to balance the internal environment of the digestive system.

Mechanism of Action

The digestive process requires gastric acid to break down food; however, an overabundance of this acid can lead to irritation of the esophageal and gastric tissues. Omirex works by inhibiting the enzyme system known as the hydrogen-potassium ATPase pump, located in the parietal cells of the stomach. This inhibition reduces the final stage of acid secretion, leading to a decrease in overall gastric acidity.

Primary Indications

This medication is typically used in the management of several gastrointestinal conditions, including:

  • Gastroesophageal Reflux Disease (GERD): A condition where stomach acid frequently flows back into the tube connecting the mouth and stomach.
  • Gastric and Duodenal Ulcers: Sores that develop on the lining of the stomach or the upper part of the small intestine.
  • Zollinger-Ellison Syndrome: A rare condition characterized by the development of tumors that cause the stomach to produce too much acid.
  • Erosive Esophagitis: Inflammation and damage to the lining of the esophagus caused by persistent acid exposure.

By reducing the volume of acid present, Omirex allows the mucosal lining of the gastrointestinal tract the opportunity to recover and helps to prevent further tissue damage.

Regulatory References

  1. MedlinePlus, NIH

What side effects are possible with Omirex?

Possible Side Effects and Safety Information

The official safety profile for Omirex (Omeprazole) categorizes adverse reactions based on their frequency and the system-organ class affected, as defined by government regulatory documents. The majority of documented side effects relate to the gastrointestinal and nervous systems.

Frequency-Classified Adverse Reactions

Frequency Classification Examples (Regulatory Listing)
Common Headache, abdominal pain, diarrhea, nausea, vomiting, flatulence, and constipation.
Uncommon Insomnia, vertigo (dizziness), rash, pruritus (itching), increased liver enzymes, and peripheral swelling.
Rare Leukopenia (low white blood cells), thrombocytopenia (low platelets), severe hypersensitivity reactions (e.g., anaphylaxis), and interstitial nephritis (kidney inflammation).

Serious Safety Warnings and Long-Term Constraints

The regulatory label includes specific warnings for rare but serious adverse reactions and risks associated with the duration of therapy. These warnings include Acute Tubulointerstitial Nephritis (ATIN) and Severe Cutaneous Adverse Reactions (SCAR).

Risks tied to long-term use are explicitly documented and include the potential for osteoporosis-related bone fractures and an increased risk of specific infections, such as Clostridium difficile-Associated Diarrhea (CDAD). Prolonged daily use is also associated with the development of Fundic Gland Polyps and the potential for deficiencies in Vitamin B-12 and magnesium (Hypomagnesemia).

Safety notes for specific populations include the consideration that patients with hepatic impairment (liver disease) may have increased exposure to the medicine, as metabolism may be slower. This official safety framework defines the known spectrum of risks, separating common, expected effects from rare, serious warnings.

Overdose and Emergency Response

Omirex Overdose and when to seek help

The official regulatory profile for Omirex (Omeprazole) overdose is defined by a consistent set of clinical manifestations and a mandatory emergency response protocol.

Documented Overdose Presentations

Overdose has been reported following ingestion of high doses, up to 2,400 mg. The officially documented clinical manifestations primarily affect the nervous and gastrointestinal systems.

System Documented Signs/Symptoms
Nervous System Headache, confusion, dizziness, drowsiness, blurred vision
Gastrointestinal Abdominal pain, nausea, vomiting
Other Tachycardia, flushing, dryness of the mouth, increased sweating

Emergency Actions and Management

Official regulatory guidance requires a specific response for any suspected overdose.

  • Mandatory Help-Seeking: In the event of a suspected or confirmed overdose, regulatory documentation mandates that immediate medical help be sought or a Poison Control Center be contacted right away. Immediate emergency services must be called if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened.
  • Antidote Status: Treatment is supportive and symptomatic, as official regulatory documents state that no specific antidote is known for Omeprazole overdose.
  • Procedural Note: Due to the substance's high protein binding, it is not readily dialyzable, underscoring the reliance on symptomatic and supportive care.

Therapeutic Uses of Omirex

Omirex: Therapeutic Uses and Treatment Goals

Omirex is prescribed to manage conditions resulting from excessive stomach acid production. Its primary therapeutic applications focus on reducing acid levels to support healing and alleviate symptoms in the upper gastrointestinal tract.

Quick Facts

  • Treats: Gastroesophageal Reflux Disease (GERD)
  • Treats: Erosive Esophagitis
  • Treats: Duodenal and Gastric Ulcers
  • Treats: Pathological Hypersecretory Conditions (e.g., Zollinger-Ellison Syndrome)
  • Treats: Helicobacter pylori Infection (in combination with specific antimicrobials)
  • Prevents: NSAID-associated Duodenal and Gastric Ulcers

The medication is used for the management of active duodenal ulcers and active benign gastric ulcers. It is also indicated for the short-term treatment of symptomatic Gastroesophageal Reflux Disease (GERD) and for the healing and maintenance of healing of erosive esophagitis, which is inflammation and injury of the esophagus caused by acid reflux.

A key benefit is its use in combination regimens to achieve Helicobacter pylori eradication, which is critical in reducing the recurrence of peptic ulcers. Furthermore, Omirex is prescribed for the long-term management of conditions involving the overproduction of gastric acid, known as pathological hypersecretory conditions.

The decision to use Omirex for any condition must be determined by a qualified healthcare professional.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Omirex?

The population eligibility for using Omirex (Omeprazole) is strictly defined by regulatory authorities based on contraindications, age, physiological state, and coexisting conditions. This information is non-advisory and drawn directly from government-approved labeling.


Absolute Contraindications

Omirex must not be used by patients with a known hypersensitivity or allergy to omeprazole, substituted benzimidazoles, or any component of the formulation. It is also contraindicated for individuals receiving co-treatment with products containing rilpivirine and, according to European labeling, with nelfinavir.


Age and Physiological Restrictions

Population Group Eligibility Status (Regulatory Wording)
Adults Approved for all labeled indications.
Children (Pediatric) Safety and effectiveness are not established in patients younger than 1 month of age. Use for GERD is approved from 1 year of age.
Hepatic Impairment Use is permitted, but may require a lower dose due to reduced clearance.
Renal Impairment No dose adjustment is needed based on official labeling.
Pregnancy Should be used only if the potential benefit justifies the potential risk.
Lactation Use is not recommended or should be avoided as a precaution.

What should I know about interactions with other medicines?

Omirex (omeprazole) can significantly alter the effectiveness and safety of many other medications. This is primarily due to its impact on stomach acidity and its interaction with liver enzymes, particularly Cytochrome P450 2C19 (CYP2C19), which is involved in drug metabolism.

Key interactions that require caution or avoidance include:


Medications with Reduced Effectiveness

Omirex reduces stomach acid, which can hinder the absorption of drugs that require an acidic environment. These include certain antifungals (e.g., itraconazole, ketoconazole, posaconazole) and some antiretrovirals (e.g., atazanavir, nelfinavir, rilpivirine). The effectiveness of the antiplatelet drug Clopidogrel is also reduced because Omirex inhibits the enzyme needed to activate it, which can increase the risk of cardiovascular events. Avoid this combination.


Medications with Increased Risk of Side Effects/Toxicity

Omirex can slow down the metabolism of other drugs metabolized by CYP2C19, leading to higher levels in the body and a greater risk of adverse effects. These include:

Drug Class/Example Potential Effect
Warfarin (blood thinner) Increased risk of bleeding (requires close INR monitoring)
Diazepam (antianxiety) Increased sedative effects
Phenytoin (anticonvulsant) Increased toxicity
Citalopram/Escitalopram (antidepressants) Increased risk of heart rhythm problems (dose adjustments may be needed)
Methotrexate (high-dose) Elevated and prolonged methotrexate levels, potentially causing toxicity

Inform your healthcare provider of all prescription, over-the-counter drugs, and herbal supplements you are taking, especially St. John's wort, as it can reduce the effectiveness of Omirex.

Mechanism of Action

The mechanism of Omirex (Omeprazole) is defined by its highly targeted action on the final biological system responsible for acid production, resulting in a sustained physiological effect.

Irreversible Deactivation of the Proton Pump

Omirex acts as a prodrug that is selectively activated only within the acidic canaliculi of the gastric parietal cells. The activated metabolite permanently targets the H^+/ K^+-ATPase enzyme—the Proton Pump—forming a covalent bond that renders the enzyme non-functional. This mechanism directly interrupts the final common pathway for acid secretion, providing profound and lasting blockade of acid secretion independent of the primary physiological stimulus.

Mechanism-Driven Duration and Onset

Because the inhibition of the Proton Pump is irreversible, the acid-suppressing effect persists until the stomach lining synthesizes and incorporates entirely new enzyme molecules. This biological constraint dictates the drug's extended duration of action and explains why maximal physiological suppression requires sequential dosing over several days, as it must target newly activated pumps to achieve the maximal extent of H^+/ K^+-ATPase inhibition.

Dosage and Administration Information

How to Use Omirex: Official Administration Guidelines

Omirex (Omeprazole) is primarily administered via the oral route as a delayed-release capsule or suspension, though an intravenous (IV) form is available for clinical settings where oral intake is not feasible.


Dosing and Frequency

The most common frequency for therapy, including the treatment and maintenance of healing for conditions like erosive esophagitis, is once daily. The standard adult starting dose typically ranges from 20 mg to 40 mg. For conditions requiring high levels of acid suppression, such as Pathological Hypersecretory Conditions (e.g., Zollinger-Ellison Syndrome), the initial dose is 60 mg once daily, and if the total daily dose exceeds 80 mg, it is administered in divided doses. For Helicobacter pylori eradication, Omeprazole is typically used in a 20 mg twice-daily regimen as part of a combination therapy.


Administration Requirements

Oral doses of Omirex must be taken before a meal, ideally in the morning to optimize acid suppression. A critical administration requirement is that the delayed-release capsule must be swallowed whole and must not be crushed or chewed, as this would damage the enteric coating necessary for effective absorption. If a patient is unable to swallow the capsule, the enteric-coated pellets may be mixed with a small amount of a slightly acidic soft food, like applesauce, and consumed immediately. Dose adjustments may be necessary for patients with severe hepatic impairment, but are generally not required for older adults or those with renal impairment.

Recent Clinical Evidence

Research Evidence Overview: Clinical Studies for Omirex

The clinical evaluation of Omirex (Omeprazole) has been conducted through extensive research, primarily using randomized controlled trials (RCTs), systematic reviews, and meta-analyses. Regulatory bodies rely on these studies when evaluating the use of the medicine for conditions linked to stomach acid. This overview summarizes the types of research and the study goals for each key approved application, adhering to findings described in official reports.


Evidence for Healing Ulcers and Erosive Esophagitis

Research has explored the medicine's use for the short-term management of active duodenal and gastric ulcers and erosive esophagitis (EE), focusing on outcomes linked to inflammatory or irritative states. The main outcomes research monitored included the endoscopic healing rate. Systematic reviews describe patterns of healing reported across trials in adult populations. Research does not determine the need for subsequent long-term therapy; the acute healing studies focus on short-term outcomes.

Evidence for Managing Acid Reflux Symptoms (GERD)

Studies explored short-term symptom changes and applied in research contexts involving fluctuating or unstable symptoms. The key outcomes research monitored were patient-reported outcomes describing perceived discomfort. Long-term outcomes related to episodic symptom patterns for non-erosive GERD are not fully established. The majority of randomized controlled trial data is restricted to short-term changes.


Research on Eradication of H. pylori

Omirex was studied for its application as a component within a combination regimen for managing Helicobacter pylori infection in conditions like peptic ulcer disease. The outcomes research monitored included the laboratory-confirmed rate of changes in bacterial status. The patterns reported in initial studies may differ from recent experiences due to evolving patterns of antibiotic resistance. Variability in findings related to resistance suggests research is ongoing to further examine different combination patterns.

Research Gaps and Uncertainties

Limited information is available for long-term outcomes, as controlled trials generally did not extend beyond 12 months. Data for certain groups, specifically infants under 12 months, remain insufficient to fully establish a clear pattern for symptom changes. Findings were mixed with non-treatment groups, leading to low certainty in the evidence for episodic symptom patterns in this age category.

Key Studies & References

  1. Omeprazole Delayed-Release Capsules, USP: Full Prescribing Information and Medication Guide
  2. Proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: an updated systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Omirex (FAQ)

Q: Can Omirex be taken with common over-the-counter pain relievers?

Official regulatory documents on Omirex primarily focus on interactions with specific prescription medications and certain herbal supplements. These sources do not typically list common over-the-counter pain relievers, such as acetaminophen or NSAIDs (like ibuprofen), as having a required contraindication or dose adjustment warning. Regulatory practice emphasizes the importance of sharing a complete list of all medications and supplements with a healthcare provider.

Q: Are there any specific supplements or vitamins that should be avoided with Omirex?

Official labeling notes that using Omirex for a prolonged period can lead to deficiencies in important nutrients, specifically Vitamin B-12 and magnesium. Additionally, the official product information indicates that the herbal supplement St. John's wort can reduce the effectiveness of Omirex. Regulatory documents describe that monitoring may be considered by a healthcare provider for long-term use, vitamin deficiencies, or potential herbal interactions.

Q: How long does it typically take to notice the effects of Omirex?

Studies and official information indicate that the acid-reducing effect begins relatively quickly, often within one hour after the dose is taken, and reaches its peak effect in about two hours. However, because of the drug’s mechanism, achieving the maximal physiological reduction in acid requires taking the medicine consistently over several days.

Q: Does Omirex interact with alcohol in a significant way?

Regulatory documents generally indicate there is no known direct interaction between Omirex (omeprazole) and alcohol that significantly affects the drug's safety or metabolism in the body. However, consuming alcohol is known to increase stomach acid production, which could potentially work against the intended effect of Omirex.

Q: Can Omirex affect my ability to drive or operate machinery?

The official safety profile lists certain side effects, such as vertigo (dizziness) and changes in vision, that may temporarily affect balance and awareness. Official labeling suggests caution may be warranted until an individual understands how the medicine affects them.

Q: What are the signs of a severe allergic reaction to Omirex?

Severe allergic reactions (hypersensitivity reactions) to Omirex are rare, but the official labeling describes specific warning signs. These can include swelling of the face, tongue, or throat (angioedema), as well as breathing difficulty. The regulatory label describes that these symptoms represent a serious event and generally require immediate medical attention.

Q: How does Omirex affect laboratory test results?

Official product information states that Omirex can alter the results of certain lab tests. Prolonged use can cause low levels of magnesium and Vitamin B-12, which are visible in blood tests. Additionally, the medicine can elevate levels of a substance called Chromogranin A (CgA), potentially interfering with diagnostic tests for neuroendocrine tumors.

Q: Are there specific genetic factors that influence how Omirex works?

Official regulatory documents note that Omirex is broken down primarily by a liver enzyme called CYP2C19. Genetic differences (polymorphisms) in how individuals process this enzyme are described in the regulatory information. This information is described in regulatory sources to explain how individual metabolism may be a factor in treatment.

Q: Does Omirex have a 'Black Box Warning' from regulatory agencies?

The prescription formulation of Omirex (omeprazole) does not currently carry a Black Box Warning (the highest-level warning) in the FDA label. However, it does include explicit warnings about serious risks like bone fractures, C. difficile diarrhea, and kidney problems.

Q: What is the difference between the immediate-release and extended-release forms of Omirex?

Omirex is supplied in a delayed-release form, meaning it has a special coating to protect the active ingredient from being destroyed by stomach acid before it can be absorbed. While Omirex is available this way, other formulations exist that are designed for immediate-release to raise stomach pH (acidity) quickly before the active ingredient is released. The delayed-release capsule form is necessary for the drug’s intended long-lasting mechanism.

Q: Is Omirex a generic drug or is it only available as a brand name?

The active ingredient in Omirex, omeprazole, is widely available as a generic medicine, as described in official health resources like NIH MedlinePlus. It is available under various brand names, and the generic version often has the same active ingredient and strength as the brand-name product.

Q: Is a prescription always required to obtain Omirex?

No, Omeprazole is available in certain lower strengths (often 20 mg) as an over-the-counter (OTC) product for treating frequent heartburn, according to official labeling. However, these OTC products are typically restricted to a short course of use, such as 14 days. Higher strengths or specific formulations may require a prescription.

Q: Can Omirex be used for pain relief?

The official indication for Omirex is to treat conditions caused by stomach acid (such as ulcers, reflux, and irritation). While reducing acid can indirectly relieve the pain associated with these specific conditions, its official pharmacological classification is as an antisecretory agent (acid reducer), not a general, systemic pain reliever.

Q: Can I stop taking Omirex suddenly, or does it require gradual discontinuation?

Regulatory safety information and clinical literature note that stopping Omirex abruptly after long-term use may sometimes lead to rebound acid hypersecretion, which is a temporary increase in stomach acid that can cause the return of heartburn symptoms. Official guidance notes that the review of any change to the treatment plan by a healthcare provider is an important safety step.

Q: Does Omirex interact with birth control pills?

Official regulatory texts addressing drug-drug interactions typically indicate that Omirex does not significantly reduce the effectiveness of hormonal contraceptives (birth control pills). No dose adjustments for oral contraceptives are generally recommended when the two medicines are taken together.

Q: What happens if I take too much Omirex by mistake?

Official regulatory documents describe that symptoms following a suspected overdose are generally reversible. These effects often include common side effects like nausea, vomiting, headache, diarrhea, and abdominal pain. The regulatory label describes that medical support is generally recommended in cases of suspected overdosage.

Q: Is Omirex an opioid or habit-forming substance?

Omirex belongs to the class of medications called Proton Pump Inhibitors (PPIs). Official sources confirm that it is not classified as a controlled substance and is not associated with the same risk of addiction as opioids or other habit-forming drugs. While stopping treatment may cause temporary rebound symptoms, this is a physiological effect, not addiction.

Q: What should I keep in mind when traveling with Omirex?

Official storage instructions are particularly important when traveling. Regulatory labels mandate keeping the capsules protected from moisture and light and avoiding excess heat. The product should always remain in its original, tightly closed container to maintain its effectiveness.

How should Omirex be stored and disposed of?

How to Store and Dispose of Omirex?

The official storage and disposal guidelines for Omirex (Omeprazole Delayed-Release) are mandatory requirements designed to protect the integrity of the acid-labile medication and ensure safety.

Official Storage Requirements

Condition Regulatory Mandate
Temperature Store at controlled room temperature (e.g., 20 C to 25 C); avoid excess heat.
Protection Keep the capsules protected from moisture and light (do not store in high-humidity areas like a bathroom).
Packaging Keep the product in the original container and ensure it is tightly closed at all times.
Child Safety Keep Omirex out of the sight and reach of children.

Official Disposal Rules

Discard any unused or expired Omirex according to local regulations. Medications should not be disposed of via wastewater (i.e., do not flush down the toilet or pour down a drain) unless the product label explicitly states otherwise. The preferred method for discarding unused medicine is using an official drug take-back location.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Omirex found in:

A-Z Index: